Pharma sector's monopolistic schemes pose rising challenges for China regulators
Investigating monopolistic practices in the pharmaceutical sector poses significant challenges, a veteran local Chinese antitrust enforcer told a recent competition conference. Since these violations are intentional, monopolistic tactics and schemes are becoming...To view the full article, register now.
Already a subscriber? Click here to view full article